<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995604</url>
  </required_header>
  <id_info>
    <org_study_id>EFLR001</org_study_id>
    <nct_id>NCT01995604</nct_id>
  </id_info>
  <brief_title>Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face</brief_title>
  <official_title>A Single Center, Double Blinded, Placebo Controlled, Randomized, Split Face Study to Evaluate the Efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of dHACM (Dehydrated Human Amnion
      Chorion Membrane) for reducing time to healing when used in post-laser recovery following
      ActiveFX™ and DeepFx™ fractionated ablative CO2 laser resurfacing of the face.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema, edema, crusting, and exudate will be compared between both groups.</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Reduction</measure>
    <time_frame>30 Days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Scarring</condition>
  <arm_group>
    <arm_group_label>dHACM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UltraPulse laser therapy with application of dHACM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile 0.9% Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>UltraPulse laser therapy with application of Sterile 0.9% Saline Solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of Sterile 0.9% Saline Solution</intervention_name>
    <description>Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.</description>
    <arm_group_label>Sterile 0.9% Saline Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of dHACM</intervention_name>
    <description>Application of dHACM to half of face after UltraPulse laser therapy.</description>
    <arm_group_label>dHACM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects in good general health greater than 18 years of age

          2. Must be willing to agree to all terms of the protocol and provide a completed and
             signed informed consent, HIPAA and photography release forms

          3. Subjects planning to undergo fractionated ablative CO2 laser resurfacing to the full
             face

          4. Subject of either Fitzpatrick Skin Types I, II or III

               -  For female subjects of childbearing potential, they must have had a regular
                  menstrual cycle prior to study entry and is willing to use an acceptable form of
                  birth control during the entire course of the study. All systemic birth control
                  measures must be in consistent use at least 30 days prior to entry into the
                  study. A female is considered NOT to be of childbearing potential if she is
                  postmenopausal for at least one (1) year, without a uterus and/or both ovaries,
                  or has had a bilateral tubal ligation. Acceptable methods of birth control are:
                  oral contraceptives, contraceptive patches/rings/implants Norplant, Depo-Provera,
                  double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies
                  of the partner.

          5. Negative urine pregnancy test results at the time of study entry for females of
             childbearing potential, if applicable

          6. Must be willing to comply with study instructions and complete the entire course of
             the study

        Exclusion Criteria:

          1. Any uncontrolled systemic disease that is not yet stabilized for at least one (1) year

          2. A significant history or current evidence of a medical, psychological or other
             disorder that, in the investigator's opinion, would interfere with the objectives of
             the study

          3. Recently excessive exposure to sunlight or artificial UV light (e.g.: use of tanning
             beds/booths and/or sunbathing) or expectations of tanning during the time of the study
             or has used self-tanner within 7 days of study entry

          4. History of or the presence of any skin condition/disease that might interfere with the
             diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema,
             psoriasis, seborrheic dermatitis)

          5. Active bacterial, fungal, or viral infection

          6. History of Herpes Simplex Virus to the facial and/or perioral areas

          7. Known allergies or sensitivities to benzocaine, lidocaine, tetracaine, PABA
             (para-aminobenzoic acid), or other local anesthetics of the amide or ester family

          8. Known allergies to gentamicin and/or streptomycin

          9. Receiving any topical products containing alpha-hydroxy acids, salicylic acid, and
             Vitamins C or E (including derivatives of Vitamins C or E) on the face within 14 days
             prior to or during the study period, other than the ingredients of the study products

         10. Receiving and/or has had a microdermabrasion (light or medium skin peel) treatment on
             their face within 30 days prior to or during the study period

         11. Using any topical tretinoin product or derivative on their face within 12 weeks prior
             to or during the study period

         12. Receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio
             frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser
             treatments on their face must have discontinued the drug/treatment and/or had the
             procedure at least 3 months prior to entering the study

         13. History of keloids or hypertrophic scars

         14. Use of systemic retinoids, prescription or over-the-counter grade within the past year

         15. A female subject who is pregnant, nursing an infant or planning a pregnancy during the
             study

         16. Current participation or completed participation of a clinical research study for an
             investigational drug or device within 30 days prior to the start of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchel P Goldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Cosmetic Laser Medical Associates of LaJolla, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>June 12, 2014</last_update_submitted>
  <last_update_submitted_qc>June 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

